Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 48NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Hodgkin Disease 1

Interventions

Specimen Handling 95Biopsy 79Magnetic Resonance Spectroscopy 74Paclitaxel 56Cyclophosphamide 53Cisplatin 53Radiotherapy 51Carboplatin 50Gemcitabine 43Bortezomib 38Irinotecan 37Taxes 32Fluorouracil 32Radiation 30veliparib 29Filgrastim 29Doxorubicin 29Vorinostat 27Oxaliplatin 27Leucovorin 27Ipilimumab 27alvocidib 26Cytarabine 26Temozolomide 25aldesleukin 24Rituximab 24fludarabine 23Etoposide 23Decitabine 23temsirolimus 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NIH × Leukapheresis × Clear all
NCT01087294 2026-06-01

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
85 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡